A clinical trial of intraoperative near-infrared imaging to assess tumor extent and identify residual disease during anterior mediastinal tumor resection

Jarrod D. Predina, Jane Keating, Andrew Newton, Christopher Corbett, Leilei Xia, Michael Shin, Lydia Frenzel Sulyok, Charuhas Deshpande, Leslie Litzky, Shuming Nie, John C. Kucharczuk, Sunil Singhal

Research output: Contribution to journalArticle

Abstract

Background: The management of most solid tumors of the anterior mediastinum involves complete resection. Because of their location near mediastinal structures, wide resection is not possible; therefore, surgeons must use subjective visual and tactile cues to determine disease extent. This clinical trial explored intraoperative near-infrared (NIR) imaging as an approach to improving tumor delineation during mediastinal tumor resection. Methods: Twenty-five subjects with anterior mediastinal lesions suspicious for malignancy were enrolled in an open-label feasibility trial. Subjects were administered indocyanine green (ICG) at a dose of 5 mg/kg, 24 hours before resection (via a technique called TumorGlow). The NIR imaging systems included Artemis (Quest, Middenmeer, the Netherlands) and Iridium (VisionSense Corp, Philadelphia, Pennsylvania). Intratumoral ICG uptake was evaluated. The clinical value was determined via an assessment of the ability of NIR imaging to detect phrenic nerve involvement or incomplete resection. Clinical and histopathologic variables were analyzed to determine predictors of tumor fluorescence. Results: No drug-related toxicity was observed. Optical imaging added a mean of 10 minutes to case duration. Among the subjects with solid tumors, 19 of 20 accumulated ICG. Fluorescent tumors included thymomas (n = 13), thymic carcinomas (n = 4), and liposarcomas (n = 2). NIR feedback improved phrenic nerve dissection (n = 4) and identified residual disease (n = 2). There were no false-positives or false-negatives. ICG preferentially accumulated in solid tumors; this was independent of clinical and pathologic variables. Conclusions: NIR imaging for anterior mediastinal neoplasms is safe and feasible. This technology may provide a real-time tool capable of determining tumor extent and specifically identify phrenic nerve involvement and residual disease.

Original languageEnglish (US)
Pages (from-to)807-817
Number of pages11
JournalCancer
Volume125
Issue number5
DOIs
StatePublished - Mar 1 2019

Fingerprint

Clinical Trials
Indocyanine Green
Neoplasms
Phrenic Nerve
Thymoma
Mediastinal Neoplasms
Iridium
Liposarcoma
Aptitude
Optical Imaging
Touch
Mediastinum
Drug-Related Side Effects and Adverse Reactions
Netherlands
Cues
Dissection
Fluorescence
Technology

Keywords

  • anterior mediastinum
  • indocyanine green (ICG)
  • intraoperative imaging
  • optical imaging
  • surgery
  • thymoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A clinical trial of intraoperative near-infrared imaging to assess tumor extent and identify residual disease during anterior mediastinal tumor resection. / Predina, Jarrod D.; Keating, Jane; Newton, Andrew; Corbett, Christopher; Xia, Leilei; Shin, Michael; Frenzel Sulyok, Lydia; Deshpande, Charuhas; Litzky, Leslie; Nie, Shuming; Kucharczuk, John C.; Singhal, Sunil.

In: Cancer, Vol. 125, No. 5, 01.03.2019, p. 807-817.

Research output: Contribution to journalArticle

Predina, JD, Keating, J, Newton, A, Corbett, C, Xia, L, Shin, M, Frenzel Sulyok, L, Deshpande, C, Litzky, L, Nie, S, Kucharczuk, JC & Singhal, S 2019, 'A clinical trial of intraoperative near-infrared imaging to assess tumor extent and identify residual disease during anterior mediastinal tumor resection', Cancer, vol. 125, no. 5, pp. 807-817. https://doi.org/10.1002/cncr.31851
Predina, Jarrod D. ; Keating, Jane ; Newton, Andrew ; Corbett, Christopher ; Xia, Leilei ; Shin, Michael ; Frenzel Sulyok, Lydia ; Deshpande, Charuhas ; Litzky, Leslie ; Nie, Shuming ; Kucharczuk, John C. ; Singhal, Sunil. / A clinical trial of intraoperative near-infrared imaging to assess tumor extent and identify residual disease during anterior mediastinal tumor resection. In: Cancer. 2019 ; Vol. 125, No. 5. pp. 807-817.
@article{7cd9a7d2bf9e40b682fdcfbbea9dd561,
title = "A clinical trial of intraoperative near-infrared imaging to assess tumor extent and identify residual disease during anterior mediastinal tumor resection",
abstract = "Background: The management of most solid tumors of the anterior mediastinum involves complete resection. Because of their location near mediastinal structures, wide resection is not possible; therefore, surgeons must use subjective visual and tactile cues to determine disease extent. This clinical trial explored intraoperative near-infrared (NIR) imaging as an approach to improving tumor delineation during mediastinal tumor resection. Methods: Twenty-five subjects with anterior mediastinal lesions suspicious for malignancy were enrolled in an open-label feasibility trial. Subjects were administered indocyanine green (ICG) at a dose of 5 mg/kg, 24 hours before resection (via a technique called TumorGlow). The NIR imaging systems included Artemis (Quest, Middenmeer, the Netherlands) and Iridium (VisionSense Corp, Philadelphia, Pennsylvania). Intratumoral ICG uptake was evaluated. The clinical value was determined via an assessment of the ability of NIR imaging to detect phrenic nerve involvement or incomplete resection. Clinical and histopathologic variables were analyzed to determine predictors of tumor fluorescence. Results: No drug-related toxicity was observed. Optical imaging added a mean of 10 minutes to case duration. Among the subjects with solid tumors, 19 of 20 accumulated ICG. Fluorescent tumors included thymomas (n = 13), thymic carcinomas (n = 4), and liposarcomas (n = 2). NIR feedback improved phrenic nerve dissection (n = 4) and identified residual disease (n = 2). There were no false-positives or false-negatives. ICG preferentially accumulated in solid tumors; this was independent of clinical and pathologic variables. Conclusions: NIR imaging for anterior mediastinal neoplasms is safe and feasible. This technology may provide a real-time tool capable of determining tumor extent and specifically identify phrenic nerve involvement and residual disease.",
keywords = "anterior mediastinum, indocyanine green (ICG), intraoperative imaging, optical imaging, surgery, thymoma",
author = "Predina, {Jarrod D.} and Jane Keating and Andrew Newton and Christopher Corbett and Leilei Xia and Michael Shin and {Frenzel Sulyok}, Lydia and Charuhas Deshpande and Leslie Litzky and Shuming Nie and Kucharczuk, {John C.} and Sunil Singhal",
year = "2019",
month = "3",
day = "1",
doi = "10.1002/cncr.31851",
language = "English (US)",
volume = "125",
pages = "807--817",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - A clinical trial of intraoperative near-infrared imaging to assess tumor extent and identify residual disease during anterior mediastinal tumor resection

AU - Predina, Jarrod D.

AU - Keating, Jane

AU - Newton, Andrew

AU - Corbett, Christopher

AU - Xia, Leilei

AU - Shin, Michael

AU - Frenzel Sulyok, Lydia

AU - Deshpande, Charuhas

AU - Litzky, Leslie

AU - Nie, Shuming

AU - Kucharczuk, John C.

AU - Singhal, Sunil

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background: The management of most solid tumors of the anterior mediastinum involves complete resection. Because of their location near mediastinal structures, wide resection is not possible; therefore, surgeons must use subjective visual and tactile cues to determine disease extent. This clinical trial explored intraoperative near-infrared (NIR) imaging as an approach to improving tumor delineation during mediastinal tumor resection. Methods: Twenty-five subjects with anterior mediastinal lesions suspicious for malignancy were enrolled in an open-label feasibility trial. Subjects were administered indocyanine green (ICG) at a dose of 5 mg/kg, 24 hours before resection (via a technique called TumorGlow). The NIR imaging systems included Artemis (Quest, Middenmeer, the Netherlands) and Iridium (VisionSense Corp, Philadelphia, Pennsylvania). Intratumoral ICG uptake was evaluated. The clinical value was determined via an assessment of the ability of NIR imaging to detect phrenic nerve involvement or incomplete resection. Clinical and histopathologic variables were analyzed to determine predictors of tumor fluorescence. Results: No drug-related toxicity was observed. Optical imaging added a mean of 10 minutes to case duration. Among the subjects with solid tumors, 19 of 20 accumulated ICG. Fluorescent tumors included thymomas (n = 13), thymic carcinomas (n = 4), and liposarcomas (n = 2). NIR feedback improved phrenic nerve dissection (n = 4) and identified residual disease (n = 2). There were no false-positives or false-negatives. ICG preferentially accumulated in solid tumors; this was independent of clinical and pathologic variables. Conclusions: NIR imaging for anterior mediastinal neoplasms is safe and feasible. This technology may provide a real-time tool capable of determining tumor extent and specifically identify phrenic nerve involvement and residual disease.

AB - Background: The management of most solid tumors of the anterior mediastinum involves complete resection. Because of their location near mediastinal structures, wide resection is not possible; therefore, surgeons must use subjective visual and tactile cues to determine disease extent. This clinical trial explored intraoperative near-infrared (NIR) imaging as an approach to improving tumor delineation during mediastinal tumor resection. Methods: Twenty-five subjects with anterior mediastinal lesions suspicious for malignancy were enrolled in an open-label feasibility trial. Subjects were administered indocyanine green (ICG) at a dose of 5 mg/kg, 24 hours before resection (via a technique called TumorGlow). The NIR imaging systems included Artemis (Quest, Middenmeer, the Netherlands) and Iridium (VisionSense Corp, Philadelphia, Pennsylvania). Intratumoral ICG uptake was evaluated. The clinical value was determined via an assessment of the ability of NIR imaging to detect phrenic nerve involvement or incomplete resection. Clinical and histopathologic variables were analyzed to determine predictors of tumor fluorescence. Results: No drug-related toxicity was observed. Optical imaging added a mean of 10 minutes to case duration. Among the subjects with solid tumors, 19 of 20 accumulated ICG. Fluorescent tumors included thymomas (n = 13), thymic carcinomas (n = 4), and liposarcomas (n = 2). NIR feedback improved phrenic nerve dissection (n = 4) and identified residual disease (n = 2). There were no false-positives or false-negatives. ICG preferentially accumulated in solid tumors; this was independent of clinical and pathologic variables. Conclusions: NIR imaging for anterior mediastinal neoplasms is safe and feasible. This technology may provide a real-time tool capable of determining tumor extent and specifically identify phrenic nerve involvement and residual disease.

KW - anterior mediastinum

KW - indocyanine green (ICG)

KW - intraoperative imaging

KW - optical imaging

KW - surgery

KW - thymoma

UR - http://www.scopus.com/inward/record.url?scp=85058714668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058714668&partnerID=8YFLogxK

U2 - 10.1002/cncr.31851

DO - 10.1002/cncr.31851

M3 - Article

C2 - 30561757

AN - SCOPUS:85058714668

VL - 125

SP - 807

EP - 817

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -